Publications: group B Streptococcus

2000 to Present:

  • Centers for Disease Control and Prevention. 2019. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2019 pdf icon[1 page].
  • McGee L, Chochua S, Li Z, et al. Multistate, Population-Based Distributions of Candidate Vaccine Targets, Clonal Complexes, and Resistance Features of Invasive Group B Streptococci Within the United States, 2015-2017. Clin Infect Dis. 2021;72(6):1004-1013.
  • Kobayashi M, McGee L, Chochua S, et al. Low but Increasing Prevalence of Reduced Beta-lactam Susceptibility Among Invasive Group B Streptococcal Isolates, US Population-Based Surveillance, 1998-2018. Open Forum Infect Dis. 2020;8(2):ofaa634. Published 2020 Dec 21.
  • Hamdan L, Vandekar S, Spieker AJ, et al. Epidemiological Trends of Racial Differences in Early- and Late-Onset Group B Streptococcus Disease in Tennessee [published online ahead of print, 2020 Oct 8]. Clin Infect Dis. 2020;ciaa1511.
  • Centers for Disease Control and Prevention. 2018. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2018.
  • Francois Watkins LK, McGee L, Schrag SJ, et al. Epidemiology of Invasive Group B Streptococcal Infections Among Nonpregnant Adults in the United States, 2008-2016. JAMA Intern Med. 2019;179(4):479-488.
  • Nanduri SA, Petit S, Smelser C, et al. Epidemiology of Invasive Early-Onset and Late-Onset Group B Streptococcal Disease in the United States, 2006 to 2015: Multistate Laboratory and Population-Based Surveillance [published correction appears in JAMA Pediatr. 2019 Mar 1;173(3):296] [published correction appears in JAMA Pediatr. 2019 May 1;173(5):502]. JAMA Pediatr. 2019;173(3):224-233.
  • Centers for Disease Control and Prevention. 2017. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2017.
  • Pitts SI, Maruthur NM, Langley GE, et al. Obesity, Diabetes, and the Risk of Invasive Group B Streptococcal Disease in Nonpregnant Adults in the United States. Open Forum Infect Dis. 2018;5(6):ofy030. Published 2018 Jun 8.
  • Hawkins PA, Law CS, Metcalf BJ, et al. Cross-resistance to lincosamides, streptogramins A and pleuromutilins in Streptococcus agalactiae isolates from the USA. J Antimicrob Chemother. 2017 Jul 1:72(7):1886-1892.
  • Metcalf BJ, Chochua S, Gertz RE Jr, et al. Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive Streptococcus agalactiae recovered in the United States.external icon Clin Microbiol Infect. 2017 Aug:23(8).
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2016 pdf icon[1 page].
  • Schrag SJ, Farley MM, Petit S, et al. Epidemiology of Invasive Early-Onset Neonatal Sepsis, 2005-2014. Pediatrics, Dec 2016; 138(6): e20162013-e20162013.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2015 pdf icon[1 page].
  • Smith EM, Khan MA, Reingold A, Watt JP. Group B streptococcus infections of soft tissue and bone in California adults, 1995-2012. Epidemiol Infect. 2015 Nov;143(15):3343-50.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2014 pdf icon[1 page].
  • Kim SY, Russell L, Park J, et al. Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa. Vaccine. 2014; 32(17):1954-63.
  • Park C, Nichols M., Schrag, SJ. Two Cases of Invasive Vancomycin-Resistant Group B Streptococcus New Engl J Med 2014; 370(9):885-86.
  • Verani J, Spina NL, Lynfield R, et al. Early-Onset Group B Streptococcal Disease in the United States: Potential for Further Reduction. Obstet Gynecol. 2014; 123(4): 828-37.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2013 pdf icon[1 page].
  • Fairlie, T, Zell, ER, Schrag, SJ. Effectiveness of Intrapartum Antibiotic Prophylaxis for Prevention of Early-Onset Group B Streptococcal Disease.  Obstetrics and Gynecology, 2013; 121(3): 570-7.
  • Madhi SA, Dangor Z, Heath PT, et al. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.external icon Vaccine. 2013 Aug 28;31 Suppl 4:D52-7. doi: 10.1016/j.vaccine.2013.02.029.
  • Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: Experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine. 2013 Aug 28;31 Suppl 4:D20-6.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2012 pdf icon[1 page].
  • Koumans EH, Rosen J, Van Dyke MK, Zell E, Phares CR, Taylor A, Loft J, and Schrag S for the ABCs and DHAP/RTI team. Prevention of mother-to-child transmission of infections during pregnancy: implementation of recommended interventions, United States, 2003-2004. Am J of Obstet Gynecology. 2012 Feb; 206(2):158.e1-158.e11.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2011 pdf icon[1 page].
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2010 pdf icon[1 page].
  • Centers for Disease Control and Prevention. Prevention of Perinatal Group B Streptococcal Disease — Revised Guidelines from CDC, 2010. Morb Mortal Wkly Rep, 2010; Vol 59:RR-10.
  • Centers for Disease Control and Prevention. Trends in perinatal group B streptococcal disease – United States, 2000-2006. Morb Mortal Wkly Rep 2009;58(5):109-12.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2009 pdf icon[1 page].
  • Kothari NJ, Morin CA, Glennen A, Jackson D, Harper J, Schrag SJ, Lynfield R. Invasive group B streptococcal disease in the elderly, Minnesota, USA, 2003-2007. Emerg Infect Dis 2009;15(8):1279-81.
  • Skoff TH, Farley MM, Petit S, et al. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. Clin Infect Dis 2009;49(1):85-92.
  • Van Dyke MK, Phares CR, Lynfield R, et al. Evaluation of Universal Antenatal Screening for Group B Streptococcus. New Engl J Med 2009; 360(25):2626-36.
  • Castor M, Whitney CG, Como-Sabetti K, et al. Antibiotic Resistance Patterns in Invasive Group B Streptococcal Isolates. Infect Dis Obstet Gynecol 2008:727505,2008.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2008 pdf icon[1 page].
  • Dahesh S, Hensler ME, Van Sorge NM, et al. Point Mutation in the Group B Streptococcal pbp2x Gene Conferring Decreased Susceptibility to Beta-Lactam Antibiotics.  Antimicrob Agents Chemother 2008;52(8):2915-8.
  • Jordan HT, Farley MM, Craig A, et al. Revisiting the Need for Vaccine Prevention of Late-Onset Neonatal Group B Streptococcal Disease: A Multi-State, Population-Based Analysis.  Ped Infect Dis J 2008;27:1057-64.
  • Phares CR, Lynfield R, Farley MM, et al. Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999-2005. JAMA 2008;299(17):2056-65.
  • Phares, CR, Schuchat, A, Schrag S.J.  Invasive group B streptococcal disease in the United States.  JAMA. 2008;300(14):1650.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2007 pdf icon[1 page].
  • Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2007; 299(17):2056-65.
  • Centers for Disease Control and Prevention. Perinatal group B streptococcal disease after universal screening recommendations — United States, 2003-2005. Morb Mortal Wkly Rep 2007;56(28):701-5.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2006 pdf icon[1 page].
  • Schrag SJ, Hadler J, Arnold KE, et al. Risk factors for invasive perinatal Escherichia coli sepsis in the era of widespread intrapartum antibiotic use. Pediatrics 2006;118(2):570-6.
  • Schrag SJ, Stoll BJ. Early-onset neonatal sepsis in the era of wide-spread intrapartum chemoprophylaxis. Ped Infect Dis J 2006;25(10):939-40.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2005 pdf icon[1 page].
  • Centers for Disease Control and Prevention. Early-Onset and Late-Onset Neonatal Group B Streptococcal Disease – United States, 1996-2004. MMWR Morb Mortal Wkly Rep 2005;54(47):1205-8.
  • Eisenberg E, Craig AS, Gautam S et al. Prevention Strategies for perinatal group B streptococcal disease: beyond screening. Ped Infect Dis J 2005;24:520-4.
  • Law MR, Palomaki G, Alfirevic Z, et al. The prevention of neonatal group B streptococcal disease: a report by a working group of the Medical Screening Society. J Med Screen 2005;12:60-8.
  • Morin CA, White K, Schuchat A, Danila RN, Lynfield R. Perinatal group B streptococcal disease prevention, Minnesota. Emerg Infect Dis 2005;11(9):1467-9.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2004 pdf icon[1 page].
  • Centers for Disease Control and Prevention. Diminishing Racial disparities in early-onset neonatal group B streptococcal disease, United States, 2000 – 2003. MMWR Morb Mortal Wkly Rep 2004; 53 (No.RR-23): 502-5.
  • Centers for Disease Control and Prevention. Laboratory Practices for Prenatal Group B Streptococcal Disease. MMWR Morb Mortal Wkly Rep 2004; 53 (No.RR-23): 506-9.
  • Balter S, Zell ER, O’Brien K, et al. Impact of intrapartum antibiotics on the care and evaluation of the newborn.  Pediatr Infect Dis 2003;22:853-7.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2003 pdf icon[1 page].
  • Moore MR. Schrag SJ. Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect Dis 2003;3(4):201-13.
  • Schrag SJ, Arnold KE, Mohle-Boetani JC, Lynfield R, Zell ER, Stefonek K, Noga H, Craig AS, Sanza LT, Smith G, Schuchat A. Prenatal Screening for Infectious Diseases and Opportunities for Prevention. Obstet Gynecol 2003;102:753-60.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2002 pdf icon[1 page].
  • Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease. MMWR Morb Mortal Wkly Rep 2002;51(No.RR-11):1-22.
  • Hyde TB, Hilger TM, Reingold A, Farley MM, O’Brien KL, and Schuchat A for the Active Bacterial Core surveillance (ABCs) of the Emerging Infections Program Network. Trends in the incidence and antimicrobial resistance of early-onset sepsis: population-based surveillance in San Francisco and Atlanta. Pediatrics 2002;110(4):690-5.
  • Schrag SJ, Zell ER, Lynfield R, et al. A population-based comparison of strategies to prevent early onset group B streptococcal disease in neonates. New Engl J Med 2002;347:233-9.
  • Schuchat A, Roome A, Zell ER, Linardos H, Zywicki S, O’Brien KL. Integrated monitoring of a new group B streptococcal disease prevention program and other perinatal infections. Maternal Child Health J 2002;6(2):107-14.
  • Baltimore RS, Huie SM, Meek JI, Schuchat A, O’Brien KL. Early-onset neonatal sepsis in the era of group B streptococcal prevention. Pediatrics 2001;108(5):1094-8.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2001 pdf icon[1 page].
  • Farley MM. Group B Streptococcal Infections in Nonpregnant Adults.  Clin Infect Dis 2001;33:556-61.
  • Henning KJ, Hall EL, Dwyer DM, Billmann L, Schuchat A, Johnson JA, Harrison LH. Invasive group B streptococcal disease in Maryland nursing home residents. J Infect Dis 2001;183:1138-42.
  • Schuchat A. Group B streptococcal infections: from trials and tribulations to triumph and trepidation. Clin Infect Dis 2001;33:751-6.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2000 pdf icon[1 page].
  • Centers for Disease Control and Prevention. Adoption of perinatal group B streptococcal disease prevention recommendations by prenatal-care providers- Connecticut and Minnesota. MMWR Morb Mortal Wkly Rep 2000; 49(11):228-32.
  • Centers for Disease Control and Prevention. Early-onset group B streptococcal disease, United States, 1998-1999. MMWR Morb Mortal Wkly Rep 2000;49(35):793-6.
  • Centers for Disease Control and Prevention. Hospital-based policies for prevention of perinatal group B streptococcal disease, United States 1999. MMWR Morb Mortal Wkly Rep 2000; 49(41):936-40.
  • Factor SH, Whitney CG, Zywicki SS, Schuchat A for the Active Bacterial Core Surveillance Team. Effects of hospital policies based on 1996 group B streptococcal disease consensus guidelines. Obstet Gynecol 2000;95:377-82.
  • Hager WD, Schuchat A, Gibbs R, Sweet R, Mead P, Larsen JW. Prevention of perinatal group B streptococcal infection: addressing current controversies. Obstet Gynecol 2000;96:141-5.
  • Schrag S, Whitney CG, Schuchat A. Neonatal group B streptococcal disease: How infection control teams can contribute to prevention efforts. Infect Control Hosp Epidemiol 2000:473-83.
  • Schrag SJ, Zywicki S, Farley M, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000;342:15-20.
  • Schuchat A, Schrag S. Group B Streptococcus: from emerging infection to prevention success story. In: Scheld WM, Craig WA, Hughes JM.  Emerging Infections 4.  Washington, DC: American Society for Microbiology; 2000:107-20.

 Top of Page

 1995-1999:

  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 1999.
  • Centers for Disease Control and Prevention. Laboratory practices for prenatal group B streptococcal screening and reporting. MMWR Morb Mortal Wkly Rep. 1999;48(20):426-8.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 1998.
  • Centers for Disease Control and Prevention. Adoption of hospital policies for prevention of perinatal group B streptococcal disease – United States, 1997. MMWR Morb Mortal Wkly Rep. 1998;47(32):665-70.
  • Harrison LH, Elliot JA, Libonati JP, et al. Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. J Infect Dis. 1998;177:998-1002.
  • Wessels MR, Kasper DL, Johnson KD, Harrison LH. Antibody responses in invasive group B streptococcal infection in adults. J Infect Dis. 1998;178:569-72.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 1997.
  • Centers for Disease Control and Prevention. Decreasing incidence of perinatal group B streptococcal disease — United States, 1993-1995. MMWR Morb Mortal Wkly Rep. 1997;46(21):473-7.
  • Rosenstein NE , Schuchat A, and the Neonatal Group B Streptococcal Disease Study Group. Opportunities for prevention of perinatal group B streptococcal disease: a multi-state surveillance analysis. Obstet Gynecol. 1997;90:901-6.
  • Whitney C, Plikaytis BD, Gozansky W, Schuchat A, Neonatal group B streptococcal disease study group. Prevention practices for perinatal group B streptococcal disease: a multistate surveillance analysis. Obstet Gynecol. 1997;89:28-32.
  • Blumberg HM, Stephens DS, Modansky M, et al. Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis. 1996;173:365-73.
  • Jackson L, Farley M, Schuchat A. Adult group B streptococcal disease. Ann Int Med. 1996;125;152-3.
  • Schuchat A, Whitney C, Zangwill K. Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR Morb Mortal Wkly Rep. 1996;45 (RR-7):1-24.
  • Farley MM. Group B streptococcal infection in older patients: Spectrum of disease and management strategies. Drugs and Aging. 1995;6:293-300.
  • Harrison LH, Ali A, Dwyer DM, et al. Relapsing invasive group B streptococcal infection in adults. Ann Intern Med. 1995;123:421-7.
  • Jackson L, Hilsdon R, Farley M, et al. Risk factors for group B streptococcal disease in adults. Ann Intern Med. 1995;123:415-20.

 Top of Page

1992-1994:

  • Schuchat A, Deaver-Robinson K, Plikaytis BD, Zangwill KM, Mohle-Boetani J, Wenger JD. Multistate case-control study of maternal risk factors for neonatal group B streptococcal disease. Pediatr Infect Dis J. 1994;13:623-9.
  • Farley MM, Harvey RC, Stull T, et al. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med. 1993;328:1807-11.
  • Mohle-Boetani JC, Schuchat A, Plikaytis BD, Smith JD, Broome CV. Comparison of prevention strategies for neonatal group B streptococcal infection: A population-based economic analysis. JAMA. 1993;270:1442-8.
  • Zangwill KM, Schuchat A, Wenger JD, and the Group B Streptococcal Disease Study Group. Group B streptococcal disease in the United States: Report from a multistate active surveillance system. MMWR Morb Mortal Wkly Rep. 1992;41[No. SS-6]:25-32.

 Top of Page